- Home
- AUTL vs MLYS Comparison
AUTL vs MLYS Comparison
Compare AUTL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- MLYS
- Stock Information
- Founded
- AUTL 2014
- MLYS 2019
- Country
- AUTL United Kingdom
- MLYS United States
- Employees
- AUTL N/A
- MLYS N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- MLYS Health Care
- Exchange
- AUTL Nasdaq
- MLYS Nasdaq
- Market Cap
- AUTL 609.4M
- MLYS 634.6M
- IPO Year
- AUTL 2018
- MLYS 2023
- Fundamental
- Price
- AUTL $2.22
- MLYS $9.24
- Analyst Decision
- AUTL Strong Buy
- MLYS Strong Buy
- Analyst Count
- AUTL 3
- MLYS 2
- Target Price
- AUTL $10.20
- MLYS $30.00
- AVG Volume (30 Days)
- AUTL 1.4M
- MLYS 259.6K
- Earning Date
- AUTL 03-13-2025
- MLYS 11-11-2024
- Dividend Yield
- AUTL N/A
- MLYS N/A
- EPS Growth
- AUTL N/A
- MLYS N/A
- EPS
- AUTL N/A
- MLYS N/A
- Revenue
- AUTL $10,091,000.00
- MLYS N/A
- Revenue This Year
- AUTL $851.83
- MLYS N/A
- Revenue Next Year
- AUTL $264.18
- MLYS N/A
- P/E Ratio
- AUTL N/A
- MLYS N/A
- Revenue Growth
- AUTL 82.71
- MLYS N/A
- 52 Week Low
- AUTL $2.07
- MLYS $8.28
- 52 Week High
- AUTL $7.37
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- AUTL 38.18
- MLYS 32.12
- Support Level
- AUTL $2.18
- MLYS $8.60
- Resistance Level
- AUTL $2.38
- MLYS $9.97
- Average True Range (ATR)
- AUTL 0.16
- MLYS 0.88
- MACD
- AUTL 0.01
- MLYS -0.31
- Stochastic Oscillator
- AUTL 7.94
- MLYS 13.25
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.